Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 15 Recurrence 7 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, T-Cell, Peripheral 3 Glioblastoma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Sarcoma 2 Primary Myelofibrosis 2 Neoplasms 2 Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Carcinoma, Squamous Cell 2 Waldenstrom Macroglobulinemia 1 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Richter's Transformation 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasms, Plasma Cell 1 Neoplasms by Site 1 Myeloproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Liposarcoma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1

Interventions

Prednisone 92 Docetaxel 66 enzalutamide 64 Abiraterone Acetate 62 Leuprolide 45 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 41 abiraterone 29 apalutamide 26 bicalutamide 23 Prednisolone 23 pembrolizumab 20 Zoledronic Acid 20 Goserelin 20 radium Ra 223 dichloride 19 darolutamide 19 cabazitaxel 15 Triptorelin Pamoate 14 sipuleucel-T 12 luprolide acetate gel depot 12 Androgen Antagonists 12 Dexamethasone 11 olaparib 10 Injections 10 gallium 68 PSMA-11 9 Pluvicto 9 Mitoxantrone 9 Ipilimumab 9 Cyclophosphamide 8 relugolix 7 orteronel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02146833 2023-01-26

SHIP

Karyopharm Therapeutics Inc

Phase 2 Terminated

20 enrolled 13 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡